Clinical trials: Vascular And Immunologic Diseases
Lymphoma, Waldenström Macroglobulinemia (WM)
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
- Conditions
- Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL
- Trial name
- NCT07249905
- Testing
- MDX2003
- Where
- 6 sites in Australia, Israel
- Volunteers
- 180 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Scleroderma (Limited and Diffuse), Undifferentiated Connective Tissue Disease
Metabolomic Analysis of Systemic Sclerosis
Currently investigators do not have diagnostic and prognostic markers for SSc which almost always starts with a vascular disease (Raynaud's disease) isolated for several years.
- Conditions
- Scleroderma (Limited and Diffuse), Undifferentiated Connective Tissue Disease, Raynaud Disease, Vascular Disease
- Trial name
- SCLEROMICS (NCT02298777)
- Testing
- - Skin biopsy - Urine sample - Blood sample
- Where
- 4 sites in France
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Recurrent Plasma Cell Myeloma
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant.
- Trial name
- NCT03622775
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
This study aims to investigate the prognostic value of circulating plasma cells (CPCs) in patients with multiple myeloma and explore whether CPCs detection might be used in place of bone marrow aspiration for disease monitoring.
- Trial name
- NCT06228794
- Testing
- Peripheral blood test
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Stroke, Action Speed
Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease
A large series of recent studies have documented the frequency of the slowing of the action in brain diseases, especially vascular and neurodegenerative diseases.
- Conditions
- Stroke, Action Speed, Dementia Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- QTOAS (NCT05785156)
- Testing
- quick tests
- Where
- France
- Volunteers
- 129 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Multiple Myeloma
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
This is a phase II multi-center, open label, single arm study to evaluate the safety and efficacy of Isatuximab administered intravenously in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a…
- Trial name
- NCT04786028
- Testing
- Isatuximab
- Where
- 7 sites in Canada
- Volunteers
- 72 people
- Sponsor
- Canadian Myeloma Research Group
Relapsed/Refractory Multiple Myeloma
An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
An open label, single-arm clinical study evaluating the safety and efficacy of ICI201 infusion in relapsed/refractory multiple myeloma
- Trial name
- NCT05980507
- Testing
- ICI201
- Where
- China
- Sponsor
- The First Affiliated Hospital of Soochow University
Coronary Heart Disease, Dyslipidemia
Cardiovascular Risk Factor Management in HIV Infection
There is growing evidence that antiretroviral therapy (ART) increases the risk of coronary heart disease (CHD) through metabolic side effects, such as dyslipidemia, insulin resistance, and type II diabetes.
- Conditions
- Coronary Heart Disease, Dyslipidemia, Diabetes Mellitus, Non-Insulin-Dependent, HIV Infection
- Trial name
- NCT00264394
- Testing
- Updated CHD risk profiles, Guidelines
- Where
- 7 sites in Switzerland
- Volunteers
- 4,097 people
- Sponsor
- University Hospital, Basel, Switzerland
Herpesviridae Infection, HTLV-I Infection
Assessment of Patients With Multiple Sclerosis (MS)
Multiple sclerosis (MS) is a disease of the nervous system. The exact cause of MS is unknown, but it is believed to be an autoimmune condition.
- Conditions
- Herpesviridae Infection, HTLV-I Infection, Multiple Sclerosis, Tropical Spastic Paraparesis
- Trial name
- NCT00001156
- Where
- United States
- Volunteers
- 1,388 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Hereditary Angioedema
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema
The main aim of the study is to check for side effects from icatibant in children and teenagers with hereditary angioedema (HAE).
- Trial name
- NCT04654351
- Testing
- TAK-667
- Where
- 3 sites in Japan
- Volunteers
- 2 people
- Sponsor
- Takeda
Ovarian Cancer, AIDS-related Kaposi Sarcoma
Doxil/Caelyx BE Study
The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities.
- Conditions
- Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
- Trial name
- NCT05567601
- Testing
- DOXIL/CAELYX
- Where
- 14 sites in India
- Volunteers
- 36 people
- Sponsor
- Baxter Healthcare Corporation
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
The goal of this clinical trial is to evaluate whether the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) is safe and capable of inducing an immune response in patients aged 12 to 59 years with autoimmune…
- Conditions
- Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Juvenile Systemic Lupus Erythematosus
- Trial name
- BTNDV-ARD (NCT07087912)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 477 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Chronic Idiopathic Urticaria
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
The study is a Phase II, dose-ranging, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of a single subcutaneously administered omalizumab dose as add-on therapy for the…
- Trial name
- NCT00866788
- Testing
- omalizumab, H1 antihistamines, Diphenhydramine
- Volunteers
- 90 people
- Sponsor
- Genentech, Inc.
Sarcoidosis, Pulmonary Hypertension
Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis
Progressive pulmonary sarcoidosis occurs in up to twenty percent of patients who require persistent treatment, but available treatment options have shown considerable long-term toxicity and uncertain or unproven efficacy.
- Trial name
- BOPSAC (NCT00926627)
- Testing
- bosentan
- Where
- 2 sites in Austria
- Volunteers
- 32 people
- Sponsor
- Daniel Doberer
Multiple Myeloma
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.
- Trial name
- NCT06105554
- Testing
- Belumosudil mesylate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoidosis, Pulmonary Hypertension
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Hypothesis: Ambrisentan (Letairis ®) is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis
- Trial name
- NCT00851929
- Testing
- Ambrisentan
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Medical University of South Carolina
Multiple Myeloma
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different Belantamab Mafodotin doses in combination with lenalidomide and dexamethasone.
- Trial name
- BelaRd (NCT04808037)
- Testing
- Belantamab mafodotin
- Where
- Greece
- Volunteers
- 66 people
- Sponsor
- Hellenic Society of Hematology
Follicular Lymphoma, Mantle Cell Lymphoma
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas.
- Conditions
- Follicular Lymphoma, Mantle Cell Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma
- Trial name
- NCT06340737
- Testing
- CD22CART Infusion
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Stanford University
Multiple Myeloma, Caregiver Subjective Burden
The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study
The purpose of this observational study is to estimate the burden of multiple myeloma on patients and caregivers in terms of QoL.
- Conditions
- Multiple Myeloma, Caregiver Subjective Burden, Quality of Life (QOL)
- Trial name
- NCT06610045
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- PeriPharm
Multiple Myeloma
MInimal Residual Disease Adapted Strategy
IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates.
- Trial name
- MIDAS (NCT04934475)
- Testing
- Isatuximab, ASCT
- Where
- 73 sites in Belgium, France and 1 more
- Volunteers
- 791 people
- Sponsor
- Intergroupe Francophone du Myelome
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.